2020 年肿瘤学审批：大流行期间的首例之年。
Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
机构信息
Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
出版信息
Nat Rev Clin Oncol. 2021 Mar;18(3):129-130. doi: 10.1038/s41571-021-00477-1.
Abstract
In 2020, despite challenges related to the COVID-19 pandemic, the US FDA approved 30 new drugs and biologic agents, 45 supplemental drug and biologic applications and 1 biosimilar application in oncology.
摘要
2020 年，尽管受到 COVID-19 大流行相关挑战的影响，美国 FDA 仍批准了 30 种新的药物和生物制剂、45 项药物和生物制剂补充申请以及 1 项肿瘤学生物类似药申请。
相似文献
1
Oncology approvals in 2020: a year of firsts in the midst of a pandemic.2020 年肿瘤学审批：大流行期间的首例之年。
Nat Rev Clin Oncol. 2021 Mar;18(3):129-130. doi: 10.1038/s41571-021-00477-1.
2
Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.多终点和审批途径的使用描绘了 FDA 肿瘤药物批准的十年历程。
Clin Cancer Res. 2013 Jul 15;19(14):3722-31. doi: 10.1158/1078-0432.CCR-13-0316. Epub 2013 May 10.
3
New Indications and Approvals for Anticancer Drugs.抗癌药物的新适应症与批准情况
Am J Nurs. 2021 Dec 1;121(12):16-17. doi: 10.1097/01.NAJ.0000803180.17463.0b.
4
2011 FDA drug approvals.2011年美国食品药品监督管理局批准的药物
Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. doi: 10.1038/nrd3657.
5
This Time I Mean It!这次我是认真的！
J Natl Compr Canc Netw. 2020 Jan;18(1):1. doi: 10.6004/jnccn.2020.0003.
6
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.2008 年至 2016 年美国食品药品监督管理局批准的肿瘤学和血液学药物概述。
J Natl Cancer Inst. 2019 May 1;111(5):449-458. doi: 10.1093/jnci/djy130.
7
New drug approvals in oncology.肿瘤学新药审批。
Nat Rev Clin Oncol. 2020 Mar;17(3):140-146. doi: 10.1038/s41571-019-0313-2. Epub 2020 Feb 4.
8
Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.美国食品和药物管理局批准用于治疗主要癌症与次要癌症的药物的监管特点和关键研究设计。
Eur J Clin Pharmacol. 2019 Sep;75(9):1193-1200. doi: 10.1007/s00228-019-02695-0. Epub 2019 May 25.
9
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.美国食品药品监督管理局对2011 - 2017年批准的肿瘤学新分子实体的反向翻译：抗癌药物开发的经验教训
Clin Transl Sci. 2018 Mar;11(2):123-146. doi: 10.1111/cts.12527. Epub 2017 Dec 19.
10
Assessing tumor-related signs and symptoms to support cancer drug approval.评估肿瘤相关体征和症状以支持癌症药物获批。
J Biopharm Stat. 2004 Feb;14(1):5-21. doi: 10.1081/BIP-120028503.
引用本文的文献
1
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.FDA 批准概要：地西他滨和西达本胺片剂用于骨髓增生异常综合征。
Clin Cancer Res. 2022 Aug 15;28(16):3411-3416. doi: 10.1158/1078-0432.CCR-21-4498.
2
Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress.大流行期间的临床证据生成：持续进展的经验教训。
Cancer J. 2022;28(2):151-156. doi: 10.1097/PPO.0000000000000589.
3
US Food and Drug Administration regulatory updates in neuro-oncology.美国食品和药物管理局神经肿瘤学监管动态更新。
J Neurooncol. 2021 Jul;153(3):375-381. doi: 10.1007/s11060-021-03789-5. Epub 2021 Jun 22.
本文引用的文献
1
The Globalization of Geriatric Oncology: From Data to Practice.老年肿瘤学的全球化：从数据到实践。
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-9. doi: 10.1200/EDBK_279513.
Zotero 插件